On Demand ACAAI 2022 Annual Scientific Meeting General Sessions

Cost: $345 for College members, $425 for non-members.

You can earn up to 56.75 AMA PRA Category 1 Credits™. This collection covers sessions from Friday, Saturday, Sunday, and Monday.

Sessions included:

  • Integrative Modalities in Allergy & Immunology Practice
  • Atopic Dermatitis: Triggers, Mimics and Treatments
  • Real World Alternatives to Traditional SCIT
  • Lessons Learned on Primary Prevention of Food Allergy
  • Looking for Zebras in Diagnosing PIDD
  • Be Aware of the Copycat -- Asthma Mimickers
  • Evaluation and Management of non-IgE Food Allergy
  • Opening Ceremony and 80th Anniversary Presentation
  • Presidential Plenary - Food Allergy - Where Are We in 2022?
  • Drug Hypersensitivity Reactions in 2022: What Should We Know?
  • Physician Health, Wellness and Burnout
  • Decision Thresholds for Management Recommendations
  • EAACI - Novel Insights into the Endotype of Allergic Asthma
  • Anaphylaxis Practice Parameter Update
  • The Asthma Patient: What Would You Do?
  • Editor's Pick - Best Articles from Annals of Allergy, Asthma and Immunology
  • Hot Topics and Practical Pearls in Dermatology
  • Management of Primary Immunodeficiency Beyond Immunoglobulin Replacement
  • Plenary - Practicing Allergy/Immunology into the Future
  • Mastering Biologics Used in Atopic Conditions
  • 7 for 11 - Hot Topics in Pediatrics A&I - A Joint Presentation from AAP-SOAI & ACAAI
  • Managing CRSwNP in the Office: Putting it all Together
  • Updates on Urticaria and Advice in Angioedema
  • Introductory Course in Rhinolaryngoscopy - Didactic
  • Allergen Mixing in the Allergist's Office - Session One: The Changing Environment in Allergy and Immunology Extract Mixing
  • Jeopardy: What's That Rash, Doctor? Dermatology
  • Coding and Government Relations
  • Addressing the Mental Health Impact on Patients, Parents, Families
  • In the News at ABAI
  • Utilizing Genetic Testing to Manage Immunodeficiency
  • Allergen Mixing in the Allergist’s Office - Session Two: The Compliant Mixing Room
  • Breastfeeding and Maternal Diet in Eczema and Food Allergies
  • Plenary - Implementing New Guidelines Into Practice
  • World Allergy Organization Forum: New Approaches to Drug Allergies
  • How Do I Know if Allergy Shots are Working?
  • Advances in Food Allergy Immunotherapy
  • Aspirin Desensitization vs Biologic Therapy for Patients with AERD
  • The Management of COVID for the Allergist / Immunologist
  • Hybrid Care: The Use of Remote Patient Monitoring in Clinical Practice
  • Infections, Microbiome and Bacteriotherapies in Atopic Dermatitis
  • Treatment of Non-Th2 Asthma

Release Date: 12/5/2022
Expiration Date: 12/4/2025

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 55.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Academic allergists including training program and division directors
  • Allergy/immunology fellows in training
  • Physician assistants and advanced practice nurses
  • Allied health professionals
  • Primary care physicians and other medical professionals

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Identify major advances in key areas of cutting-edge research in immunologic mechanisms and allergic responses.
  • Demonstrate knowledge of basic processes linking molecular and cellular biology and genetics with allergic pathophysiology and immunodeficiency.
  • Translate emerging clinical science principles to clinical practice in patients with allergic and immunologic diseases.
  • Evaluate and implement state-of-the-art diagnostic and therapeutic strategies for treating patients with allergic and immunologic diseases.
  • Explain the impact of environmental exposures and external influences on patients with allergic disorders.
  • Recognize emerging trends in the prevalence of allergic and immunologic disorders and discuss their impact on public health.
  • Evaluate the impact of new diagnostic and therapeutic strategies on health care costs and outcomes.
  • Discuss processes, tools and technologies for the efficient allergy and immunology practice.
Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 56.75 AMA PRA Category 1 Credit™
  • 56.75 Attendance
Course opens: 
Course expires: 

Available Credit

  • 56.75 AMA PRA Category 1 Credit™
  • 56.75 Attendance
Please login or create an account to take this course.
Please login or create an account to take this course.
Please login or create an account to take this course.
Please login or create an account to take this course.
Please login or create an account to take this course.


Please login or create an account to take this course.